Mar 30, 2022 / 01:00PM GMT
Peter Salzmann - Immunovant, Inc. - CEO & Director
Good morning. I'm Pete Salzmann, Chief Executive Officer of Immunovant, and I'm excited to welcome you to Immunovant's R&D Day where we have an opportunity to dive deeper into our asset, our program and our opportunity.
We'll be making some forward-looking statements over the course of the day, and investors should carefully read this slide available on our website and in the 8-K we filed this morning.
Before we jump in, I'd like to cover some housekeeping for how we'll handle Q&A from the audience. We're very interested to address any questions that you may have, and so throughout the day, please use the chat function to submit your questions, which we will address at the end of the program. If you'd like to submit them anonymously, that's okay too.
I'm going to kick things off today with a brief company and asset overview, after which we'll cover information related to our 3 announced indications.
As most of you know, Immunovant was established with a dedicated purpose: To advance the development of
Immunovant Inc To Host R&D Day (Virtual) Transcript
Mar 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers